$400m Heptares acquisition to drive Sosei's R&D
This article was originally published in Scrip
Executive Summary
Sosei is to pay up to $400m to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies. It will pay $180m in cash up front and up to $220m contingent on pipeline milestones and future deals bringing in revenues.
You may also be interested in...
Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.
Heptares-Powered Sosei's Incoming CEO Explains What Happens Next
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.